A Whole New Crop

Dolan, Kerry A.
June 2008
Forbes Asia;6/2/2008, Vol. 4 Issue 10, p50
The article presents information on the technology zinc finger which is being moved towards the market by Dow AgroSciences LLC. Zinc fingers are naturally occurring proteins that bind to DNA and control vast amounts of genetic information. Zinc finger can turn specific genes off or on or to some point in between, delete genes altogether or add new genetic material. It reports that Sangamo BioSciences Inc. controls most of the intellectual property around zinc finger research.


Related Articles

  • Sangamo's lead zinc-finger therapy flops in diabetic neuropathy. Eisenstein, Michael // Nature Biotechnology;Feb2012, Vol. 30 Issue 2, p121 

    The article reports on the announcement of Sangamo Biosciences that it will halt its SB-509 program in diabetic neuropathy after the zinc-finger protein (ZFP) therapy failed to meet its end points. Despite its decision, the company remains buoyant about ZFP as therapeutic platform. Sangamo...

  • The zinc finger nuclease monopoly. Scott, Christopher Thomas // Nature Biotechnology;Aug2005, Vol. 23 Issue 8, p915 

    The article reports that Sangamo Biosciences Inc. holds key patents and trade secrets not only on the design of zinc fingers and zinc finger chimeric endonucleases (ZFNs), but also on their uses in drug discovery and the regulation of gene expression. Engineering a ZFN to introduce a...

  • Genentech Licenses Sangamo's ZFP Technology For Proteins. Boggs, Jennifer // BioWorld Today;5/1/2007, Vol. 18 Issue 84, p1 

    The article reports that Sangamo BioSciences Inc. granted rights allowing Genentech Inc. to use its zinc finger deoxyribonucleic acid (DNA)-binding protein technology to enhance protein production. The benefits of the agreement to Sangamo include an up-front fee and technology access fee. Other...

  • With Patents, Light Touch Can Be More Useful Than Iron Grip. Breindl, Anette // BioWorld Insight;12/26/2012, Vol. 20 Issue 52, p3 

    The article focuses on a new genome editing technique based on transcription activator-like effector nucleases (TALENs) and its developer company Sangamo Biosciences Inc., which is developing zinc finger nuclease technology in several therapeutic areas. It adds that zinc finger nucleases are...

  • Genentech Licenses ZFP Technology For Proteins.  // Bioworld Week;5/7/2007, Vol. 15 Issue 19, p3 

    The article reports that Sangamo BioSciences Inc. granted rights to Genentech Inc. that allows the company to use its zinc finger deoxyribonucleic acid-binding protein (ZFP) technology to enhance protein production. Sangamo will be entitled to an up-front fee, and an ongoing technology access...

  • Zinc Finger Protein Has Therapeutic Potential in Drug Discovery.  // PharmaGenomics;Jul/Aug2003, Vol. 3 Issue 6, p14 

    Focuses on a research which determined the therapeutic potential of zinc finger protein in drug discovery. Information on zinc finger DNA binding protein; Details of a gene therapy technology being developed by scientists at Sangamo BioSciences Inc.; Challenges of the gene engineering technology.

  • Sangamo Adds Gene Therapy Assets with Ceregene Buyout. Shaffer, Catherine // BioWorld Today;8/28/2013, Vol. 24 Issue 165, p1 

    The article reports on the acquisition by clinical state biopharmaceutical firm Sangamo BioSciences Inc. of biotechnology firm Ceregene in 2013. The Phase II Alzheimer's disease gene therapy CERE-110 and a device for brain delivery are included in the buyout deal. Sangamo Chief Executive Officer...

  • Genome-editing tools storm ahead. Marx, Vivien // Nature Methods;Nov2012, Vol. 9 Issue 11, p1055 

    The article offers information on gene editing tools. It informs that Sangamo BioSciences Inc. is sponsoring clinical trials which are utilizing zinc-finger nuclease (ZFN), gene editors which cut DNA at a predetermined point. It also informs that Sangamo BioSciences Inc. has made an agreement...

  • Companies vie for a cut of the gene-editing market. Grushkin, Daniel // Nature Medicine;Jul2011, Vol. 17 Issue 7, p759 

    The article offers information on various companies that are competing for a place in gene-editing market. It mentions that the zinc finger nucleases (ZFNs) of Sangamo BioSciences Inc. continue to be the best-know gene-editing technique for adult cells. It says that Horizon Discovery Ltd. in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics